Navigation Links
Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
Date:7/30/2009

issued and sold in the private placement and no placement agent was used in connection with the private placement.

Senesco primarily intends to utilize the net proceeds of these transactions to further advance its multiple myeloma research and development program with the goal of initiating a Phase I clinical trial.

"We are excited by the potential of SNS-101 as a novel treatment alternative for multiple myeloma," said Allen Cato, MD, PhD, CEO of Cato Research. "Our recent investment reflects our confidence in the Company's regulatory and development plans. We look forward to significant progress in the months ahead."

"We are gratified by the confidence expressed in us by our CRO, the Board members and accredited investors involved in this transaction," commented Joel Brooks, Chief Financial Officer. "This funding, along with the $1 million in financing secured several weeks ago, enables us to continue moving forward efficiently with our goal of filing an Investigational New Drug Application and initiating a Phase I clinical trial for SNS-01."

Important Information

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The shares of common stock have been sold pursuant to an exemption from state and federal securities laws.

In connection with the private placement, the Company will prepare a proxy statement for the Company's stockholders to be filed with the Securities and Exchange Commission (the "SEC"). The proxy statement will contain information about the Company, the private placement and related matters. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY WHEN IT IS AVAILABL
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
2. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
3. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
4. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
5. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
6. Senesco Technologies to Present at BIO 2008 Business Forum
7. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
8. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
9. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
10. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
(Date:7/30/2014)... 30, 2014 Adding to their already ... boat special – Buy 2 of any Weighing ... will benefit lab technicians looking for durable and reliable ... ideal for multiple applications including weighing liquids, solid, or ... choices including diamond-shaped, hexagonal, square, aluminum weighing, and standard ...
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report Strategic ... report provides in-depth analysis of the current trends ... capital segments of the financial industry, bearing in ... impact on the future of emerging biotechnology companies ... identifies regions of the world that are attracting ...
(Date:7/29/2014)... 29, 2014 Human Longevity, Inc. (HLI), a ... on extending the healthy, high performance human life span, ... Ph.D., an expert in machine learning and machine translation ... HLI from Google where he was Distinguished Research Scientist ... directly to HLI Co-Founder and CEO, J. Craig ...
Breaking Biology Technology:RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today ... up to $185 million in exchange for rights ... American sales of Lexiscan(TM),(regadenoson) injection. CV Therapeutics received ... receive a potential future milestone payment,of $10 million., ...
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... Dr. Anders,Kolb of the Nemours Center for Childhood ... Pediatric Sarcomas" was,presented today at the American Association ... being held in San Diego, California from,April 12-16, ...
Cached Biology Technology:CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 2CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection 3Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
(Date:7/30/2014)... cells can develop into a multitude of cells types. Researchers ... the specific types of mature cells that make up the ... key seems to be long chains of sugars that dangle ... at the University of California, San Diego, has created synthetic ... can be more easily manipulated to direct the process, they ...
(Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... not be the first state that comes to mind. But it,s ... in Illinois and 1,500 acres of wine grapes. One acre ... though more commonly it,s $3,000 to $5,000. The largest wineries in ... 10,000 per year. "In many cases, growing wine grapes ...
... lacking access to clean, safe drinking water, scientists are ... new filtering technology that kills up to 98 percent ... A report on the technology appears in Nano ... Yi Cui and colleagues explain that most water ...
... new evidence that the fat tissue in those spare tires ... storage depot for surplus calories is an active organ ... perhaps increasing the risk of heart attacks, cancer, and other ... other substances not previously known to be secreted into the ...
Cached Biology News:Taming wild grapes for better wine 2Taming wild grapes for better wine 3
... UltraClean GelSpin Kit utilizes a silica based spin ... After electrophoresis, the desired DNA band is cut ... the spin filter unit. The gel slice is ... Then the DNA is bound to the silica ...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
Biology Products: